ArriVent BioPharma (AVBP) reported a Q3 net loss Thursday of $0.61 per diluted share, narrowing from a loss of $5.52 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.82 per share.
As expected, no revenue for the quarter ended Sept. 30 was reported.
As of Sept. 30, the clinical-stage biopharmaceutical company said it had $282.9 million in cash and cash equivalents that could fund operations into 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。